Oxygenta Pharma Reports Strong Financial Performance in Q2 FY25

Nov 16 2024 05:17 PM IST
share
Share Via
Oxygenta Pharmaceutical, a microcap company in the pharmaceuticals and drugs industry, has reported positive financial results for the quarter ending September 2024. Despite a 'Sell' call from MarketsMojo, the company's PAT has increased by 130.17% and net sales have reached a five-quarter high. This shows a promising trend for the company's financial performance.

Oxygenta Pharmaceutical, a microcap company in the pharmaceuticals and drugs industry, has recently announced its financial results for the quarter ending September 2024. The company’s stock has been given a ‘Sell’ call by MarketsMOJO.

Despite this, Oxygenta Pharma has shown positive financial performance in the second quarter of the fiscal year 2024-2025. The company’s score has improved from 21 to 10 in the last three months.


According to the September 2024 financials, Oxygenta Pharma has seen a significant growth in its Profit After Tax (PAT) for the nine-month period, with a 130.17% increase compared to the same period last year. This indicates a very positive trend for the company’s PAT.


In terms of net sales, Oxygenta Pharma has recorded its highest quarterly sales in the last five quarters, at Rs 14.01 crore. This also shows a positive trend in the company’s sales in the near term.


Furthermore, the company’s PAT for the nine-month period is higher at Rs 3.56 crore compared to the preceding 12-month period ending in September 2024, which was at Rs -15.53 crore. This indicates a significant improvement in the company’s financial performance in just nine months, surpassing its sales for the entire previous year.


Overall, Oxygenta Pharmaceutical has shown promising financial results for the quarter ending September 2024, with a positive trend in both its PAT and net sales. Investors may want to keep an eye on this microcap company in the pharmaceutical industry.


{{stockdata.stock.stock_name.value}} Live

{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)

{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)


Our weekly and monthly stock recommendations are here
Loading...
{{!sm.blur ? sm.comp_name : ''}}
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Entry Price
Target Price
{{sm.target_price }} ({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News